生物技术药物药代动力学特点与检测.pptVIP

生物技术药物的药代动力学特点及检测;Cumulative Revenues of Selected Biotechnology Companies (Amgen, Genentech, Chiron, Genzyme and Biogen);Selected Blockbuster Protein Pharmaceuticals;生物技术药物;蛋白肽类药物药代动力学;蛋白肽类药物吸收;Correlation between MW and the cumulative recovery of sc rINF alpha-2a, cytochrome c, inulin and 5-fluoro-2 -deoxyuridine (FUDR) in the efferent lymph in sheep;蛋白肽类药物吸收;IM 和SC给药生物利用度;Pharmacokinetics of IM ADI-SS PEG 20,000 mw in humans with hepatocellular carcinoma;Intranasal administration;Inhalation administration;Plasma bioavailability of therapeutic peptides versus MW after pulmonary administration;Oral administration;蛋白肽类药物的分布;;蛋白肽类药物分布：血脑屏障;Ziconotide cerebrospinal CSF concentration as a function of time;CSF Ziconotide Pharmacokinetic Results by Dose Group;小分子药物代谢;小分子药物代谢;蛋白肽类药物代谢与排泄（消除：elimination);蛋白肽类药物代谢与排泄;蛋白肽类药物特点及其应用;蛋白肽类药物样品检测方法 ;ELISA法;ELISA法;ELISA法的干扰因素;Immunogenicity of native ADI and ADI-SS PEG in mice and rabbits ;SC生长激素（0.4 IU/kg）后食蟹猴(n=7-8/组)的血清生长激素浓度;普通ELISA 、高灵敏度ELISA（additional 增色放大系统）和化学发光ELISA 法(luminol/过氧化氢底物)灵敏度和线性范围比较 (From 汤仲明，2002）;放射免疫测定法和免疫放射定量法;同位素标记示踪法;同位素标记示踪法;同位素标记示踪法与其他分析手段联合应用;生物检定法;Pharmacokinetic analyses of ADI–SS PEG and ADI–SS PEG measured by enzyme and ELISA assays;生物检定法缺点;延长半衰期常用方法;Pharmacokinetic profiles for interferon (IFN)-α2a and 40 kDa polyethylene glycol (PEG)–IFN-α;IV or SC albutropin（growth hormone–albumin fusion）or GH in rats and monkeys